New approach targets cancer cells based on unique characteristics, leaving healthy cells unharmed.
A new low-intensity ultrasound approach can destroy cancer cells while leaving healthy cells unharmed.
Investigators from the California Institute of Technology and City of Hope Beckman Research Institute have developed a safer, more-targeted approach to ultrasound-based cancer therapies. This approach targets a tumor cell’s unique physical and structural properties, creating a more selective treatment.
“This project shows that ultrasound can be used to target cancer cells based on their mechanical properties,” said David Mittelstein, lead author of a paper published in Applied Physics Letters. “This is an exciting proof of concept for a new kind of cancer therapy that doesn’t require the cancer to have unique molecular markers or to be located separately from healthy cells to be targeted.”
The team scaled down the intensity and fine-tuned the frequency to match the target cells, enabling them to shatter several types of cancer cells while leaving healthy blood cells unscathed. Currently, most ultrasound-based cancer therapies use either high-intensity beams to heat and destroy cells or special contrast agents that are injected pre-ultrasound. These techniques can harm healthy cells, and contrast agents only work in a small portion of tumors.
These results are the latest step forward in a growing field called oncotripsy – the singling out and killing of cancer cells based on their physical properties. Oncotripsy is based on the idea that cells are vulnerable to ultrasound at specific frequencies, much like how a trained singer can shatter a wine glass by singing a specific note. Similarly, researchers discovered low-intensity ultrasound, at certain frequencies, breaks down the cellular skeleton of cancer cells specifically.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.